Drug updated on 10/21/2024
| Dosage Form | Ophthalmic solution (topical; 100%) |
| Drug Class | Semifluorinated alkanes |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for treatment of the signs and symptoms of dry eye disease.
Latest News
Summary
- This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
- The safety profile of perfluorohexyloctane was noted as effective and safe, though specific details on adverse events were not provided.
- Ocular treatment-emergent adverse events (TEAES) were fewer in the perfluorohexyloctane group compared to controls (MD = -0.66 ± 1.7), suggesting good tolerability of the drug.
- The safety profile was mentioned as safe, though specific details regarding adverse events were not provided.
- Perfluorohexyloctane was associated with fewer ocular treatment-emergent adverse events (MD = -0.66 ± 1.7) compared to control, indicating satisfactory tolerability.
- The studies focused on patients with Meibomian Gland Dysfunction (MGD) and evaporative dry eye disease (DED). There were no specific subgroup analyses or further population-specific findings provided.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Miebo (perfluorohexyloctane) Prescribing Information. | 2023 | Bausch & Lomb Americas Inc., Bridgewater, NJ |